FDA Approves CIRM-Funded Clinical Trial for New Stem Cell HIV Treatment
On Tuesday, Richmond-based Sangamo Biosciences received approval from FDA to conduct a clinical trial on a new stem cell therapy designed to cure HIV. For the trial, patients with HIV will be given stem cells that have been genetically modified in a way that makes them resistant to HIV infection. The trial is partially funded by the California Institute for Regenerative Medicine.
- "Possible HIV Cure OK'd for Testing" (Fikes, U-T San Diego, 3/4).